Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXQROU)

Drug Name

3-(2,4-dihydroxyphenyl)propionic acid Drug Info

Synonyms

5631-68-5; 3-(2,4-dihydroxyphenyl)propanoic acid; 3-(2,4-Dihydroxyphenyl)propionic acid; Hydroumbellic acid; Benzenepropanoic acid, 2,4-dihydroxy-; CHEMBL228155; 2,4-Dihydroxybenzenepropanoic acid; AI3-13072; AC1L3WC8; AC1Q5VW7; NCIOpen2_000618; SCHEMBL490491; ACMC-1B046; 2,4-Dihydroxyhydrocinnamic acid; CTK5A4966; DTXSID50204854; MolPort-000-877-529; HMCMTJPPXSGYJY-UHFFFAOYSA-N; ZINC388556; NSC71551; KS-00000N9R; NSC-71551; BDBM50211056; STL034241; SBB068271; BBL028276; Benzenepropanoic acid,2,4-dihydroxy-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 96384
CAS Number: CAS 5631-68-5
TTD Drug ID: DMXQROU

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[2]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[2]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[4]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[5]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[6]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[7]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[8]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[9]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Enhanced substituted resorcinol hydrophobicity augments tyrosinase inhibition potency. J Med Chem. 2007 May 31;50(11):2676-81.
2	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
3	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
4	National Cancer Institute Drug Dictionary (drug id 685201).
5	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
8	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
9	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.